FindMyKOL
Clinical trialNCT05801978RecruitingPhase 4Interventional

Durability of Vaccine Responses

NCT05801978 is a phase 4 interventional trial sponsored by Emory University. As of 21 Nov 2026, it is recruiting participants. It studies Live Attenuated Yellow Fever 17D Vaccine and Quadrivalent seasonal influenza vaccine in Vaccine Response. The registry lists an enrollment of 66 participants at 3 sites in 1 country. The registry lists a start date of 11 Apr 2023 and a primary completion date of 30 Sept 2027. One of its registered investigators has a FindMyKOL profile.

SponsorEmory University →Enrollment66Vaccine Response
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05801978
FieldValue
Registry IDNCT05801978
StatusRecruiting
PhasePhase 4
Study typeInterventional trial
Lead sponsorEmory University
Enrollment66
Registered sites3
Countries1
ConditionsVaccine Response
DrugsLive Attenuated Yellow Fever 17D Vaccine and Quadrivalent seasonal influenza vaccine
Start11 Apr 2023
Primary completion30 Sept 2027
Study completion30 Sept 2027
Last update posted17 Jul 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The ability of the vaccines today to generate a long-lasting protection against infections varies greatly from one vaccine to another. The yellow fever vaccine (YF-17D) is one of the most successful vaccines ever developed, having been administered to over 600 million people globally. A single vaccination is known to induce durable protection over several decades. In contrast, the quadrivalent influenza vaccine (QIV) generates an immunity that wanes quickly with no long-lasting protection. Currently, the duration of immune protection for new vaccines is difficult to predict during vaccine product development and can only be ascertained by a "wait and see" approach. This is due, in part, to the fact that some of the signals that activate a durable immune system protection remain unknown. This study aims to provide a better understanding of this problem by vaccinating willing participants with either the FDA-approved yellow fever vaccine or the quadrivalent influenza vaccine and collecting baseline and follow-up biologic samples to compare how the immune system reacts.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Georgia, United States3 sites, 3 recruiting
  • Emory University Hospital

    Atlanta

    Recruiting
  • Emory Winship Cancer Institute

    Atlanta

    Recruiting
  • the Hope Clinic of Emory University

    Decatur

    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgia: 3 sites, 3 recruitingGA3HawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Live Attenuated Yellow Fever 17D VaccineQuadrivalent seasonal influenza vaccine
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT05801978

Each answer restates registry values shown on this page.

What is NCT05801978?

NCT05801978 is a phase 4 interventional trial sponsored by Emory University. It studies Live Attenuated Yellow Fever 17D Vaccine and Quadrivalent seasonal influenza vaccine in Vaccine Response.

Is NCT05801978 recruiting?

As of 21 Nov 2026, it is recruiting participants. 3 of its 3 sites list their own status as recruiting.

Who leads NCT05801978?

The registry names Nadine Rouphael, MD (principal investigator, Emory University) as the overall official.

Where does NCT05801978 run?

The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT05801978 study?

The registered drug and biological interventions are Live Attenuated Yellow Fever 17D Vaccine and Quadrivalent seasonal influenza vaccine.

When is NCT05801978 expected to complete?

The registry lists a primary completion date of 30 Sept 2027 and a study completion date of 30 Sept 2027. The sponsor last updated the record on 17 Jul 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.